

Glen Mackey Joins illumiSonics Inc. as a Member of the Board of Directors



December, 2022 - illumiSonics Inc. is pleased to announce that Glen E. Mackey has joined the company as a member of the Board of Directors. Mackey is a highly accomplished corporate executive with extensive experience in governance, marketing, trading, and financial management in the financial and commodity sectors.

"We are thrilled to welcome Glen to our Board of Directors," said Parsin Haji Reza, Chair of the Board of Directors, and CTO of illumiSonics Inc. "Glen's deep industry knowledge, experience and strategic vision will be invaluable to our company as we continue to develop and commercialize our innovative products for Digital and Molecular Pathology."

Mackey is currently Chairman of the board of VRP Farms Ltd., and previously served as Chief Risk and Procurement Officer at NRG Energy, Inc. where he oversaw retail costing and structuring, cash management, insurance, procurement, and enterprise risk management activities within the NRG portfolio of companies. He also held leadership positions with KPMG, Nexen, EnCana Midstream and Marketing, Duke Energy, Westcoast Energy, Engage Energy, and TD Bank Financial Group.

Mackey has previously held advisory/board positions at Rutgers University (Mathematical Finance) Commodity Futures Trading Commission (Market Risk Advisory Committee), GenOn Energy, Mirant Novatas, and several other companies.

"I am honored to be joining the Board of Directors of illumiSonics Inc.," said Mackey. "I believe that the company has tremendous potential to revolutionize Digital and Molecular Pathology, and I look forward to working with the team to help bring their products to market."

About illumiSonics Inc.

illumiSonics Inc. is a Waterloo, Ontario company that has developed the PARS platform, a revolutionary non-contact, high-resolution, label-free, non-destructive microscope. PARS captures all light-matter interactions to give unprecedented deep data which is then processed using AI to yield multiple virtual histological stains leading to precision diagnostics. The ability to generate multiple diagnoses from a single tissue sample addresses an unmet medical need that has the potential to save lives and reduce costs. For more information, visit www.illumisonics.com.